Searched for
BIOCON BIOLOGICS CEO
'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journeyA missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Biocon shares rise 1% after billionaire Kiran Mazumdar-Shaw names niece as successorBiocon's chairperson, Kiran Mazumdar-Shaw, has named her niece, Claire Mazumdar, as her successor, sparking a more than 1% jump in the comp...
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- China pulls ahead in biologics race, forcing Indian drugmakers to rethink strategyIndia's drug companies face a tough race in the global biologics market. China is quickly becoming a leader in biotech supply chains. India...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps downBiocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...
- Biocon Biologics to introduce three new biosimilars for cancer treatmentBiocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...
- Biocon Biologics gets global rights for biosimilar AdalimumabBiocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full control over ...
- Biocon to make Biocon Biologics a wholly owned subsidiaryBiocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Bioc...
- Biocon Biologics secures market entry for Yesafili in USBiocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili...
- Biocon Biologics inks licence pact with Janssen for biosimilar productThe agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Bioco...
- Biocon Biologics takes over Viatris' biosimilar biz in over 70 countriesBiocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countr...
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Biocon Biologics appoints Shreehas Tambe as MD & CEOTambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...
- Biocon Biologics promotes Shreehas Tambe as deputy CEOA Biocon veteran, Shreehas Tambe joined the company in 1997 and has more than 20 years of leadership experience in operational and strategi...
- Biocon subsidiary acquires research facility from Pfizer HealthcareBiocon shares were trading 0.64 per cent higher that their previous close at Rs 226.85 on the BSE.
Load More
